Search

Developed by scientists at MSK and the University of British Columbia/BC Cancer, the platform provides the deepest look yet into tumor evolution.

… Thursday, November 14, 2019 VIDEO | 00:42 DLP+ in action: A liquid suspension of single cells in a glass pipette moves in front a camera linked to a microscope. When a cell is detected in the suspension, the machine moves to the right and deposits the cell on a microchip for DNA sequencing. Video courtesy

A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors.

… Thursday, October 25, 2018 Background: A preclinical study published in the journal Molecular Therapy by researchers at Memorial Sloan Kettering (MSK) provides evidence that radiation therapy could improve the efficacy of CAR T cell therapy for solid tumors. The success of chimeric antigen receptor (

The Gerstner Sloan Kettering Graduate School of Biomedical Sciences welcomed its ninth class of PhD students on July 21, 2014.

… Monday, August 25, 2014 The Gerstner Sloan Kettering Graduate School of Biomedical Sciences welcomed its ninth class of PhD students on July 21, 2014. The nine students are Steven Albanese, Jacob A. Boyer, Christopher Hulton, Nayan Jain, Nicholas F. Kuhn, Xiaoyi Li, Michelle M.E. Riegman, Benjamin Y.

Scott N. Keeney, a member of the Molecular Biology Program within the Sloan Kettering Institute, was one of 56 researchers to be appointed a Howard Hughes Medical Institute (HHMI) investigator in 2008.

… Wednesday, October 1, 2008 Summary Scott N. Keeney, a member of the Molecular Biology Program within the Sloan Kettering Institute, was one of 56 researchers to be appointed a Howard Hughes Medical Institute (HHMI) investigator in 2008. Scott N. Keeney , a member of the Molecular Biology Program within

Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn - which amounts to more than 15 percent of MSKCC's patients currently being treated in Manhattan.

… Monday, September 13, 2010 Memorial Sloan Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center , will

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s Paul Marks Prize for Cancer Research.

… Monday, November 8, 2021 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three innovative investigators as the recipients of this year’s  Paul Marks Prize for Cancer Research . The prize, named in honor of MSK’s past President Emeritus, the late Paul Marks, MD, recognizes a new generation

Scientists are using a molecule from the immune system to combat this serious complication in a new way.

… Friday, January 15, 2016 Summary Graft-versus-host disease (GVHD) is a complication of blood and marrow stem cell transplantation . A new study reveals how the patient’s immune system restores the intestinal lining following damage from GVHD and points to a strategy for a potential therapy to alleviate

Mammography has shortcomings but the price is reasonable; MRI is more effective but expensive. Two new modalities — contrast-enhanced digital mammography (CEDM) and abbreviated breast MRI (AB-MRI) — may provide the best of both.

… Thursday, June 23, 2016 Since the mid-1980s, mammography has been the primary screening modality for breast cancer. While it has reduced mortality rates, there are some notable drawbacks. Mammography fails to detect as many as 30 percent of cancers because overlying normal breast tissue obscures them

MSK’s Integrative Medicine Service focuses on empowering patients with practices — from acupuncture to music therapy — that fit seamlessly into your care plan.

… Thursday, April 10, 2025 A cancer diagnosis can make you feel as if the ground has shifted beneath you, throwing your life into a cycle of appointments, treatments, and scans. It’s common to feel waves of uncertainty or even disconnection from your own body.  MSK’s Integrative Medicine Service empowers

According to a large retrospective study co-led by Memorial Sloan Kettering Cancer Center and published in the Journal of Clinical Oncology, PTCy is an acceptable alternative to CNI-based prophylaxis in MUD HCT recipients and superior for MMUD HCT. These results will help improve minority donor participation in the NMDP registry.

… Wednesday, July 17, 2024 Post-transplantation cyclophosphamide (PTCy) led to similar overall survival (OS) and graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) in patients who received a hematopoietic stem cell transplant (HCT) from a matched unrelated donor (MUD) and those who received